CLINICAL TRIALS PROFILE FOR KYMRIAH
✉ Email this page to a colleague
All Clinical Trials for KYMRIAH
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT02529813 ↗ | CD19-Specific T-cells in Treating Patients With Advanced Lymphoid Malignancies | Active, not recruiting | Intrexon Corporation | Phase 1 | 2015-12-16 | This phase I clinical trial studies the side effects and best dose of CD19-specific T-cells in treating patients with lymphoid malignancies that have spread to other places in the body and usually cannot be cured or controlled with treatment. Sometimes researchers change the deoxyribonucleic acid (DNA) (genetic material in cells) of donated T-cells (white blood cells that support the immune system) using a process called "gene transfer." Gene transfer involves drawing blood from the patient, and then separating out the T-cells using a machine. Researchers then perform a gene transfer to change the T-cells' DNA, and then inject the changed T-cells into the body of the patient. Injecting modified T-cells made from the patient may help attack cancer cells in patients with advanced B-cell lymphoma or leukemia. |
| NCT02529813 ↗ | CD19-Specific T-cells in Treating Patients With Advanced Lymphoid Malignancies | Active, not recruiting | National Cancer Institute (NCI) | Phase 1 | 2015-12-16 | This phase I clinical trial studies the side effects and best dose of CD19-specific T-cells in treating patients with lymphoid malignancies that have spread to other places in the body and usually cannot be cured or controlled with treatment. Sometimes researchers change the deoxyribonucleic acid (DNA) (genetic material in cells) of donated T-cells (white blood cells that support the immune system) using a process called "gene transfer." Gene transfer involves drawing blood from the patient, and then separating out the T-cells using a machine. Researchers then perform a gene transfer to change the T-cells' DNA, and then inject the changed T-cells into the body of the patient. Injecting modified T-cells made from the patient may help attack cancer cells in patients with advanced B-cell lymphoma or leukemia. |
| NCT02529813 ↗ | CD19-Specific T-cells in Treating Patients With Advanced Lymphoid Malignancies | Active, not recruiting | Ziopharm | Phase 1 | 2015-12-16 | This phase I clinical trial studies the side effects and best dose of CD19-specific T-cells in treating patients with lymphoid malignancies that have spread to other places in the body and usually cannot be cured or controlled with treatment. Sometimes researchers change the deoxyribonucleic acid (DNA) (genetic material in cells) of donated T-cells (white blood cells that support the immune system) using a process called "gene transfer." Gene transfer involves drawing blood from the patient, and then separating out the T-cells using a machine. Researchers then perform a gene transfer to change the T-cells' DNA, and then inject the changed T-cells into the body of the patient. Injecting modified T-cells made from the patient may help attack cancer cells in patients with advanced B-cell lymphoma or leukemia. |
| NCT02529813 ↗ | CD19-Specific T-cells in Treating Patients With Advanced Lymphoid Malignancies | Active, not recruiting | Ziopharm Oncology | Phase 1 | 2015-12-16 | This phase I clinical trial studies the side effects and best dose of CD19-specific T-cells in treating patients with lymphoid malignancies that have spread to other places in the body and usually cannot be cured or controlled with treatment. Sometimes researchers change the deoxyribonucleic acid (DNA) (genetic material in cells) of donated T-cells (white blood cells that support the immune system) using a process called "gene transfer." Gene transfer involves drawing blood from the patient, and then separating out the T-cells using a machine. Researchers then perform a gene transfer to change the T-cells' DNA, and then inject the changed T-cells into the body of the patient. Injecting modified T-cells made from the patient may help attack cancer cells in patients with advanced B-cell lymphoma or leukemia. |
| NCT02529813 ↗ | CD19-Specific T-cells in Treating Patients With Advanced Lymphoid Malignancies | Active, not recruiting | M.D. Anderson Cancer Center | Phase 1 | 2015-12-16 | This phase I clinical trial studies the side effects and best dose of CD19-specific T-cells in treating patients with lymphoid malignancies that have spread to other places in the body and usually cannot be cured or controlled with treatment. Sometimes researchers change the deoxyribonucleic acid (DNA) (genetic material in cells) of donated T-cells (white blood cells that support the immune system) using a process called "gene transfer." Gene transfer involves drawing blood from the patient, and then separating out the T-cells using a machine. Researchers then perform a gene transfer to change the T-cells' DNA, and then inject the changed T-cells into the body of the patient. Injecting modified T-cells made from the patient may help attack cancer cells in patients with advanced B-cell lymphoma or leukemia. |
| NCT03628053 ↗ | Tisagenlecleucel vs Blinatumomab or Inotuzumab for Patients With Relapsed/Refractory B-cell Precursor Acute Lymphoblastic Leukemia | Withdrawn | Novartis Pharmaceuticals | Phase 3 | 2020-06-05 | This trial aims to compare the benefits and risks of tisagenlecleucel to blinatumomab or inotuzumab in adult patients with relapsed or refractory ALL. This trial investigates tisagenlecleucel as an additional treatment option for this patient population with high unmet medical need. |
| NCT03642626 ↗ | MT2017-45: CAR-T Cell Therapy for Heme Malignancies | Recruiting | Masonic Cancer Center, University of Minnesota | 2018-12-18 | This is a phase II study of FDA-approved CAR-T products for patients with hematologic malignancies. Patients will be assigned to Arm A and B based on age and diagnosis. Overall remission rate, safety events and other endpoints will be calculated for Arm A and B separately. | |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for KYMRIAH
Condition Name
| Condition Name for KYMRIAH | |
| Intervention | Trials |
| Recurrent Diffuse Large B-Cell Lymphoma | 3 |
| Refractory Diffuse Large B-cell Lymphoma | 3 |
| Acute Lymphoblastic Leukemia | 3 |
| Stage III Chronic Lymphocytic Leukemia | 1 |
| [disabled in preview] | 0 |
| This preview shows a limited data set Subscribe for full access, or try a Trial | |
Clinical Trial Locations for KYMRIAH
Trials by Country
Clinical Trial Progress for KYMRIAH
Clinical Trial Phase
Clinical Trial Sponsors for KYMRIAH
Sponsor Name
